Global Bio Similars & Subsequent Entry Biologic Market Insights, Forecast to 2030

Publication ID:

PB512245005

Publication Date:

December 25, 2024

Pages:

126

Publisher:

MRRPB5

Countries:

Global [1]

USD 4,900.00

Pharmaceutical Manufacturing [2]

Healthcare [3]

Pharma & Healthcare [4]

Description:

Market Analysis and Insights: Global Bio Similars & Subsequent Entry Biologic Market
The global Bio Similars & Subsequent Entry Biologic market is projected to grow from US$ million in 2024 to US$ million by 2030, at a Compound Annual Growth Rate (CAGR) of % during the forecast period.
The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during the next six years. The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U.S. dollars in 2022. The pharmaceutical market factors such as increasing demand for healthcare, technological advancements, and the rising prevalence of chronic diseases, increase in funding from private & government organizations for development of pharmaceutical manufacturing segments and rise in R&D activities for drugs. However, the industry also faces challenges such as stringent regulations, high costs of research and development, and patent expirations. Companies need to continuously innovate and adapt to these challenges to stay competitive in the market and ensure their products reach patients in need. Additionally, the COVID-19 pandemic has highlighted the importance of vaccine development and supply chain management, further emphasizing the need for pharmaceutical companies to be agile and responsive to emerging public health needs.
Report Covers:
This report presents an overview of global market for Bio Similars & Subsequent Entry Biologic market size. Analyses of the global market trends, with historic market revenue data for 2019 - 2023, estimates for 2024, and projections of CAGR through 2030.
This report researches the key producers of Bio Similars & Subsequent Entry Biologic, also provides the revenue of main regions and countries. Highlights of the upcoming market potential for Bio Similars & Subsequent Entry Biologic, and key regions/countries of focus to forecast this market into various segments and sub-segments. Country specific data and market value analysis for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, Middle East, Africa, and Other Countries.
This report focuses on the Bio Similars & Subsequent Entry Biologic revenue, market share and industry ranking of main companies, data from 2019 to 2024. Identification of the major stakeholders in the global Bio Similars & Subsequent Entry Biologic market, and analysis of their competitive landscape and market positioning based on recent developments and segmental revenues. This report will help stakeholders to understand the competitive landscape and gain more insights and position their businesses and market strategies in a better way.
This report analyzes the segments data by Type and by Application, revenue, and growth rate, from 2019 to 2030. Evaluation and forecast the market size for Bio Similars & Subsequent Entry Biologic revenue, projected growth trends, production technology, application and end-user industry.
Market Segmentation
By Company
Sun Pharma
Synthon Pharmaceuticals
Teva Pharmaceutical Industries
LG Life Sciences
Celltrion Biocon
Hospira
Merck
Biogen idec
Genentech (Roche)
Pfizer
Celltrion
Biocon
Amgen
Samsung Biologics
Mylan
Dr. Reddy's Laboratories
Stada Arzneimittel AG
AbbVie
Sanofi-Aventis
Johnson & Johnson
Novo Nordisk
Eli Lilly
Novartis
3sbio
Biotech
Gelgen
Innovent
Dong Bao
Ganlee
Segment by Type
Monoclonal Antibodies
Interferon
Erythropoietin
Insulin
Vaccines
Others
Segment by Application
Tumor
Diabetes
Cardiovascular
Hemophilia
Others
By Region
North America
United States
Canada
Europe
Germany
France
UK
Italy
Russia
Nordic Countries
Rest of Europe
China
Asia (excluding China)
Japan
South Korea
China Taiwan
Southeast Asia
India
Latin America, Middle East & Africa
Brazil
Mexico
Turkey
Israel
GCC Countries
Chapter Outline
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (product type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Revenue of Bio Similars & Subsequent Entry Biologic in global and regional level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world. This section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter 3: Detailed analysis of Bio Similars & Subsequent Entry Biologic companies鈥� competitive landscape, revenue, market share and industry ranking, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by Type, covering the revenue, and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by Application, covering the revenue, and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: North America (US & Canada) by Type, by Application and by country, revenue for each segment.
Chapter 7: Europe by Type, by Application and by country, revenue for each segment.
Chapter 8: China by Type, and by Application, revenue for each segment.
Chapter 9: Asia (excluding China) by Type, by Application and by region, revenue for each segment.
Chapter 10: Middle East, Africa, and Latin America by Type, by Application and by country, revenue for each segment.
Chapter 11: Provides profiles of key companies, introducing the basic situation of the main companies in the market in detail, including product descriptions and specifications, Bio Similars & Subsequent Entry Biologic revenue, gross margin, and recent development, etc.
Chapter 12: Analyst's Viewpoints/Conclusions

Please Note - This is an on demand report and will be delivered in 2 business days (48 hours) post payment.

Table Of Contents:

1 Report Overview
1.1 Study Scope
1.2 Market Analysis by Type
1.2.1 Global Bio Similars & Subsequent Entry Biologic Market Size Growth Rate by Type, 2019 VS 2023 VS 2030
1.2.2 Monoclonal Antibodies
1.2.3 Interferon
1.2.4 Erythropoietin
1.2.5 Insulin
1.2.6 Vaccines
1.2.7 Others
1.3 Market by Application
1.3.1 Global Bio Similars & Subsequent Entry Biologic Market Size Growth Rate by Application, 2019 VS 2023 VS 2030
1.3.2 Tumor
1.3.3 Diabetes
1.3.4 Cardiovascular
1.3.5 Hemophilia
1.3.6 Others
1.4 Assumptions and Limitations
1.5 Study Objectives
1.6 Years Considered
2 Global Growth Trends
2.1 Global Bio Similars & Subsequent Entry Biologic Market Perspective (2019-2030)
2.2 Global Bio Similars & Subsequent Entry Biologic Growth Trends by Region
2.2.1 Bio Similars & Subsequent Entry Biologic Market Size by Region: 2019 VS 2023 VS 2030
2.2.2 Bio Similars & Subsequent Entry Biologic Historic Market Size by Region (2019-2024)
2.2.3 Bio Similars & Subsequent Entry Biologic Forecasted Market Size by Region (2025-2030)
2.3 Bio Similars & Subsequent Entry Biologic Market Dynamics
2.3.1 Bio Similars & Subsequent Entry Biologic Industry Trends
2.3.2 Bio Similars & Subsequent Entry Biologic Market Drivers
2.3.3 Bio Similars & Subsequent Entry Biologic Market Challenges
2.3.4 Bio Similars & Subsequent Entry Biologic Market Restraints
3 Competition Landscape by Key Players
3.1 Global Revenue Bio Similars & Subsequent Entry Biologic by Players
3.1.1 Global Bio Similars & Subsequent Entry Biologic Revenue by Players (2019-2024)
3.1.2 Global Bio Similars & Subsequent Entry Biologic Revenue Market Share by Players (2019-2024)
3.2 Global Bio Similars & Subsequent Entry Biologic Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.3 Global Key Players of Bio Similars & Subsequent Entry Biologic, Ranking by Revenue, 2022 VS 2023 VS 2024
3.4 Global Bio Similars & Subsequent Entry Biologic Market Concentration Ratio
3.4.1 Global Bio Similars & Subsequent Entry Biologic Market Concentration Ratio (CR5 and HHI)
3.4.2 Global Top 10 and Top 5 Companies by Bio Similars & Subsequent Entry Biologic Revenue in 2023
3.5 Global Key Players of Bio Similars & Subsequent Entry Biologic Head office and Area Served
3.6 Global Key Players of Bio Similars & Subsequent Entry Biologic, Product and Application
3.7 Global Key Players of Bio Similars & Subsequent Entry Biologic, Date of Enter into This Industry
3.8 Mergers & Acquisitions, Expansion Plans
4 Bio Similars & Subsequent Entry Biologic Breakdown Data by Type
4.1 Global Bio Similars & Subsequent Entry Biologic Historic Market Size by Type (2019-2024)
4.2 Global Bio Similars & Subsequent Entry Biologic Forecasted Market Size by Type (2025-2030)
5 Bio Similars & Subsequent Entry Biologic Breakdown Data by Application
5.1 Global Bio Similars & Subsequent Entry Biologic Historic Market Size by Application (2019-2024)
5.2 Global Bio Similars & Subsequent Entry Biologic Forecasted Market Size by Application (2025-2030)
6 North America
6.1 North America Bio Similars & Subsequent Entry Biologic Market Size (2019-2030)
6.2 North America Bio Similars & Subsequent Entry Biologic Market Size by Type
6.2.1 North America Bio Similars & Subsequent Entry Biologic Market Size by Type (2019-2024)
6.2.2 North America Bio Similars & Subsequent Entry Biologic Market Size by Type (2025-2030)
6.2.3 North America Bio Similars & Subsequent Entry Biologic Market Share by Type (2019-2030)
6.3 North America Bio Similars & Subsequent Entry Biologic Market Size by Application
6.3.1 North America Bio Similars & Subsequent Entry Biologic Market Size by Application (2019-2024)
6.3.2 North America Bio Similars & Subsequent Entry Biologic Market Size by Application (2025-2030)
6.3.3 North America Bio Similars & Subsequent Entry Biologic Market Share by Application (2019-2030)
6.4 North America Bio Similars & Subsequent Entry Biologic Market Size by Country
6.4.1 North America Bio Similars & Subsequent Entry Biologic Market Size by Country: 2019 VS 2023 VS 2030
6.4.2 North America Bio Similars & Subsequent Entry Biologic Market Size by Country (2019-2024)
6.4.3 North America Bio Similars & Subsequent Entry Biologic Market Size by Country (2025-2030)
6.4.4 U.S.
6.4.5 Canada
7 Europe
7.1 Europe Bio Similars & Subsequent Entry Biologic Market Size (2019-2030)
7.2 Europe Bio Similars & Subsequent Entry Biologic Market Size by Type
7.2.1 Europe Bio Similars & Subsequent Entry Biologic Market Size by Type (2019-2024)
7.2.2 Europe Bio Similars & Subsequent Entry Biologic Market Size by Type (2025-2030)
7.2.3 Europe Bio Similars & Subsequent Entry Biologic Market Share by Type (2019-2030)
7.3 Europe Bio Similars & Subsequent Entry Biologic Market Size by Application
7.3.1 Europe Bio Similars & Subsequent Entry Biologic Market Size by Application (2019-2024)
7.3.2 Europe Bio Similars & Subsequent Entry Biologic Market Size by Application (2025-2030)
7.3.3 Europe Bio Similars & Subsequent Entry Biologic Market Share by Application (2019-2030)
7.4 Europe Bio Similars & Subsequent Entry Biologic Market Size by Country
7.4.1 Europe Bio Similars & Subsequent Entry Biologic Market Size by Country: 2019 VS 2023 VS 2030
7.4.2 Europe Bio Similars & Subsequent Entry Biologic Market Size by Country (2019-2024)
7.4.3 Europe Bio Similars & Subsequent Entry Biologic Market Size by Country (2025-2030)
7.4.3 Germany
7.4.4 France
7.4.5 U.K.
7.4.6 Italy
7.4.7 Russia
7.4.8 Nordic Countries
8 China
8.1 China Bio Similars & Subsequent Entry Biologic Market Size (2019-2030)
8.2 China Bio Similars & Subsequent Entry Biologic Market Size by Type
8.2.1 China Bio Similars & Subsequent Entry Biologic Market Size by Type (2019-2024)
8.2.2 China Bio Similars & Subsequent Entry Biologic Market Size by Type (2025-2030)
8.2.3 China Bio Similars & Subsequent Entry Biologic Market Share by Type (2019-2030)
8.3 China Bio Similars & Subsequent Entry Biologic Market Size by Application
8.3.1 China Bio Similars & Subsequent Entry Biologic Market Size by Application (2019-2024)
8.3.2 China Bio Similars & Subsequent Entry Biologic Market Size by Application (2025-2030)
8.3.3 China Bio Similars & Subsequent Entry Biologic Market Share by Application (2019-2030)
9 Asia (excluding China)
9.1 Asia Bio Similars & Subsequent Entry Biologic Market Size (2019-2030)
9.2 Asia Bio Similars & Subsequent Entry Biologic Market Size by Type
9.2.1 Asia Bio Similars & Subsequent Entry Biologic Market Size by Type (2019-2024)
9.2.2 Asia Bio Similars & Subsequent Entry Biologic Market Size by Type (2025-2030)
9.2.3 Asia Bio Similars & Subsequent Entry Biologic Market Share by Type (2019-2030)
9.3 Asia Bio Similars & Subsequent Entry Biologic Market Size by Application
9.3.1 Asia Bio Similars & Subsequent Entry Biologic Market Size by Application (2019-2024)
9.3.2 Asia Bio Similars & Subsequent Entry Biologic Market Size by Application (2025-2030)
9.3.3 Asia Bio Similars & Subsequent Entry Biologic Market Share by Application (2019-2030)
9.4 Asia Bio Similars & Subsequent Entry Biologic Market Size by Region
9.4.1 Asia Bio Similars & Subsequent Entry Biologic Market Size by Region: 2019 VS 2023 VS 2030
9.4.2 Asia Bio Similars & Subsequent Entry Biologic Market Size by Region (2019-2024)
9.4.3 Asia Bio Similars & Subsequent Entry Biologic Market Size by Region (2025-2030)
9.4.4 Japan
9.4.5 South Korea
9.4.6 China Taiwan
9.4.7 Southeast Asia
9.4.8 India
9.4.9 Australia
10 Middle East, Africa, and Latin America
10.1 Middle East, Africa, and Latin America Bio Similars & Subsequent Entry Biologic Market Size (2019-2030)
10.2 Middle East, Africa, and Latin America Bio Similars & Subsequent Entry Biologic Market Size by Type
10.2.1 Middle East, Africa, and Latin America Bio Similars & Subsequent Entry Biologic Market Size by Type (2019-2024)
10.2.2 Middle East, Africa, and Latin America Bio Similars & Subsequent Entry Biologic Market Size by Type (2025-2030)
10.2.3 Middle East, Africa, and Latin America Bio Similars & Subsequent Entry Biologic Market Share by Type (2019-2030)
10.3 Middle East, Africa, and Latin America Bio Similars & Subsequent Entry Biologic Market Size by Application
10.3.1 Middle East, Africa, and Latin America Bio Similars & Subsequent Entry Biologic Market Size by Application (2019-2024)
10.3.2 Middle East, Africa, and Latin America Bio Similars & Subsequent Entry Biologic Market Size by Application (2025-2030)
10.3.3 Middle East, Africa, and Latin America Bio Similars & Subsequent Entry Biologic Market Share by Application (2019-2030)
10.4 Middle East, Africa, and Latin America Bio Similars & Subsequent Entry Biologic Market Size by Country
10.4.1 Middle East, Africa, and Latin America Bio Similars & Subsequent Entry Biologic Market Size by Country: 2019 VS 2023 VS 2030
10.4.2 Middle East, Africa, and Latin America Bio Similars & Subsequent Entry Biologic Market Size by Country (2019-2024)
10.4.3 Middle East, Africa, and Latin America Bio Similars & Subsequent Entry Biologic Market Size by Country (2025-2030)
10.4.4 Brazil
10.4.5 Mexico
10.4.6 Turkey
10.4.7 Saudi Arabia
10.4.8 Israel
10.4.9 GCC Countries
11 Key Players Profiles
11.1 Sun Pharma
11.1.1 Sun Pharma Company Details
11.1.2 Sun Pharma Business Overview
11.1.3 Sun Pharma Bio Similars & Subsequent Entry Biologic Introduction
11.1.4 Sun Pharma Revenue in Bio Similars & Subsequent Entry Biologic Business (2019-2024)
11.1.5 Sun Pharma Recent Developments
11.2 Synthon Pharmaceuticals
11.2.1 Synthon Pharmaceuticals Company Details
11.2.2 Synthon Pharmaceuticals Business Overview
11.2.3 Synthon Pharmaceuticals Bio Similars & Subsequent Entry Biologic Introduction
11.2.4 Synthon Pharmaceuticals Revenue in Bio Similars & Subsequent Entry Biologic Business (2019-2024)
11.2.5 Synthon Pharmaceuticals Recent Developments
11.3 Teva Pharmaceutical Industries
11.3.1 Teva Pharmaceutical Industries Company Details
11.3.2 Teva Pharmaceutical Industries Business Overview
11.3.3 Teva Pharmaceutical Industries Bio Similars & Subsequent Entry Biologic Introduction
11.3.4 Teva Pharmaceutical Industries Revenue in Bio Similars & Subsequent Entry Biologic Business (2019-2024)
11.3.5 Teva Pharmaceutical Industries Recent Developments
11.4 LG Life Sciences
11.4.1 LG Life Sciences Company Details
11.4.2 LG Life Sciences Business Overview
11.4.3 LG Life Sciences Bio Similars & Subsequent Entry Biologic Introduction
11.4.4 LG Life Sciences Revenue in Bio Similars & Subsequent Entry Biologic Business (2019-2024)
11.4.5 LG Life Sciences Recent Developments
11.5 Celltrion Biocon
11.5.1 Celltrion Biocon Company Details
11.5.2 Celltrion Biocon Business Overview
11.5.3 Celltrion Biocon Bio Similars & Subsequent Entry Biologic Introduction
11.5.4 Celltrion Biocon Revenue in Bio Similars & Subsequent Entry Biologic Business (2019-2024)
11.5.5 Celltrion Biocon Recent Developments
11.6 Hospira
11.6.1 Hospira Company Details
11.6.2 Hospira Business Overview
11.6.3 Hospira Bio Similars & Subsequent Entry Biologic Introduction
11.6.4 Hospira Revenue in Bio Similars & Subsequent Entry Biologic Business (2019-2024)
11.6.5 Hospira Recent Developments
11.7 Merck
11.7.1 Merck Company Details
11.7.2 Merck Business Overview
11.7.3 Merck Bio Similars & Subsequent Entry Biologic Introduction
11.7.4 Merck Revenue in Bio Similars & Subsequent Entry Biologic Business (2019-2024)
11.7.5 Merck Recent Developments
11.8 Biogen idec
11.8.1 Biogen idec Company Details
11.8.2 Biogen idec Business Overview
11.8.3 Biogen idec Bio Similars & Subsequent Entry Biologic Introduction
11.8.4 Biogen idec Revenue in Bio Similars & Subsequent Entry Biologic Business (2019-2024)
11.8.5 Biogen idec Recent Developments
11.9 Genentech (Roche)
11.9.1 Genentech (Roche) Company Details
11.9.2 Genentech (Roche) Business Overview
11.9.3 Genentech (Roche) Bio Similars & Subsequent Entry Biologic Introduction
11.9.4 Genentech (Roche) Revenue in Bio Similars & Subsequent Entry Biologic Business (2019-2024)
11.9.5 Genentech (Roche) Recent Developments
11.10 Pfizer
11.10.1 Pfizer Company Details
11.10.2 Pfizer Business Overview
11.10.3 Pfizer Bio Similars & Subsequent Entry Biologic Introduction
11.10.4 Pfizer Revenue in Bio Similars & Subsequent Entry Biologic Business (2019-2024)
11.10.5 Pfizer Recent Developments
11.11 Celltrion
11.11.1 Celltrion Company Details
11.11.2 Celltrion Business Overview
11.11.3 Celltrion Bio Similars & Subsequent Entry Biologic Introduction
11.11.4 Celltrion Revenue in Bio Similars & Subsequent Entry Biologic Business (2019-2024)
11.11.5 Celltrion Recent Developments
11.12 Biocon
11.12.1 Biocon Company Details
11.12.2 Biocon Business Overview
11.12.3 Biocon Bio Similars & Subsequent Entry Biologic Introduction
11.12.4 Biocon Revenue in Bio Similars & Subsequent Entry Biologic Business (2019-2024)
11.12.5 Biocon Recent Developments
11.13 Amgen
11.13.1 Amgen Company Details
11.13.2 Amgen Business Overview
11.13.3 Amgen Bio Similars & Subsequent Entry Biologic Introduction
11.13.4 Amgen Revenue in Bio Similars & Subsequent Entry Biologic Business (2019-2024)
11.13.5 Amgen Recent Developments
11.14 Samsung Biologics
11.14.1 Samsung Biologics Company Details
11.14.2 Samsung Biologics Business Overview
11.14.3 Samsung Biologics Bio Similars & Subsequent Entry Biologic Introduction
11.14.4 Samsung Biologics Revenue in Bio Similars & Subsequent Entry Biologic Business (2019-2024)
11.14.5 Samsung Biologics Recent Developments
11.15 Mylan
11.15.1 Mylan Company Details
11.15.2 Mylan Business Overview
11.15.3 Mylan Bio Similars & Subsequent Entry Biologic Introduction
11.15.4 Mylan Revenue in Bio Similars & Subsequent Entry Biologic Business (2019-2024)
11.15.5 Mylan Recent Developments
11.16 Dr. Reddy's Laboratories
11.16.1 Dr. Reddy's Laboratories Company Details
11.16.2 Dr. Reddy's Laboratories Business Overview
11.16.3 Dr. Reddy's Laboratories Bio Similars & Subsequent Entry Biologic Introduction
11.16.4 Dr. Reddy's Laboratories Revenue in Bio Similars & Subsequent Entry Biologic Business (2019-2024)
11.16.5 Dr. Reddy's Laboratories Recent Developments
11.17 Stada Arzneimittel AG
11.17.1 Stada Arzneimittel AG Company Details
11.17.2 Stada Arzneimittel AG Business Overview
11.17.3 Stada Arzneimittel AG Bio Similars & Subsequent Entry Biologic Introduction
11.17.4 Stada Arzneimittel AG Revenue in Bio Similars & Subsequent Entry Biologic Business (2019-2024)
11.17.5 Stada Arzneimittel AG Recent Developments
11.18 AbbVie
11.18.1 AbbVie Company Details
11.18.2 AbbVie Business Overview
11.18.3 AbbVie Bio Similars & Subsequent Entry Biologic Introduction
11.18.4 AbbVie Revenue in Bio Similars & Subsequent Entry Biologic Business (2019-2024)
11.18.5 AbbVie Recent Developments
11.19 Sanofi-Aventis
11.19.1 Sanofi-Aventis Company Details
11.19.2 Sanofi-Aventis Business Overview
11.19.3 Sanofi-Aventis Bio Similars & Subsequent Entry Biologic Introduction
11.19.4 Sanofi-Aventis Revenue in Bio Similars & Subsequent Entry Biologic Business (2019-2024)
11.19.5 Sanofi-Aventis Recent Developments
11.20 Johnson & Johnson
11.20.1 Johnson & Johnson Company Details
11.20.2 Johnson & Johnson Business Overview
11.20.3 Johnson & Johnson Bio Similars & Subsequent Entry Biologic Introduction
11.20.4 Johnson & Johnson Revenue in Bio Similars & Subsequent Entry Biologic Business (2019-2024)
11.20.5 Johnson & Johnson Recent Developments
11.21 Novo Nordisk
11.21.1 Novo Nordisk Company Details
11.21.2 Novo Nordisk Business Overview
11.21.3 Novo Nordisk Bio Similars & Subsequent Entry Biologic Introduction
11.21.4 Novo Nordisk Revenue in Bio Similars & Subsequent Entry Biologic Business (2019-2024)
11.21.5 Novo Nordisk Recent Developments
11.22 Eli Lilly
11.22.1 Eli Lilly Company Details
11.22.2 Eli Lilly Business Overview
11.22.3 Eli Lilly Bio Similars & Subsequent Entry Biologic Introduction
11.22.4 Eli Lilly Revenue in Bio Similars & Subsequent Entry Biologic Business (2019-2024)
11.22.5 Eli Lilly Recent Developments
11.23 Novartis
11.23.1 Novartis Company Details
11.23.2 Novartis Business Overview
11.23.3 Novartis Bio Similars & Subsequent Entry Biologic Introduction
11.23.4 Novartis Revenue in Bio Similars & Subsequent Entry Biologic Business (2019-2024)
11.23.5 Novartis Recent Developments
11.24 3sbio
11.24.1 3sbio Company Details
11.24.2 3sbio Business Overview
11.24.3 3sbio Bio Similars & Subsequent Entry Biologic Introduction
11.24.4 3sbio Revenue in Bio Similars & Subsequent Entry Biologic Business (2019-2024)
11.24.5 3sbio Recent Developments
11.25 Biotech
11.25.1 Biotech Company Details
11.25.2 Biotech Business Overview
11.25.3 Biotech Bio Similars & Subsequent Entry Biologic Introduction
11.25.4 Biotech Revenue in Bio Similars & Subsequent Entry Biologic Business (2019-2024)
11.25.5 Biotech Recent Developments
11.26 Gelgen
11.26.1 Gelgen Company Details
11.26.2 Gelgen Business Overview
11.26.3 Gelgen Bio Similars & Subsequent Entry Biologic Introduction
11.26.4 Gelgen Revenue in Bio Similars & Subsequent Entry Biologic Business (2019-2024)
11.26.5 Gelgen Recent Developments
11.27 Innovent
11.27.1 Innovent Company Details
11.27.2 Innovent Business Overview
11.27.3 Innovent Bio Similars & Subsequent Entry Biologic Introduction
11.27.4 Innovent Revenue in Bio Similars & Subsequent Entry Biologic Business (2019-2024)
11.27.5 Innovent Recent Developments
11.28 Dong Bao
11.28.1 Dong Bao Company Details
11.28.2 Dong Bao Business Overview
11.28.3 Dong Bao Bio Similars & Subsequent Entry Biologic Introduction
11.28.4 Dong Bao Revenue in Bio Similars & Subsequent Entry Biologic Business (2019-2024)
11.28.5 Dong Bao Recent Developments
11.29 Ganlee
11.29.1 Ganlee Company Details
11.29.2 Ganlee Business Overview
11.29.3 Ganlee Bio Similars & Subsequent Entry Biologic Introduction
11.29.4 Ganlee Revenue in Bio Similars & Subsequent Entry Biologic Business (2019-2024)
11.29.5 Ganlee Recent Developments
12 Analyst's Viewpoints/Conclusions
13 Appendix
13.1 Research Methodology
13.1.1 Methodology/Research Approach
13.1.2 Data Source
13.2 Disclaimer
13.3 Author Details

Companies Mentioned:

Sun Pharma
Synthon Pharmaceuticals
Teva Pharmaceutical Industries
LG Life Sciences
Celltrion Biocon
Hospira
Merck
Biogen idec
Genentech (Roche)
Pfizer
Celltrion
Biocon
Amgen
Samsung Biologics
Mylan
Dr. Reddy's Laboratories
Stada Arzneimittel AG
AbbVie
Sanofi-Aventis
Johnson & Johnson
Novo Nordisk
Eli Lilly
Novartis
3sbio
Biotech
Gelgen
Innovent
Dong Bao
Ganlee

License Types:

Single User License (PDF)

This license allows for use of a publication by one person.
This person may print out a single copy of the publication.
This person can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.
This person cannot share the publication (or any information contained therein) with any other person or persons.
Unless a Enterprise License is purchased, a Single User License must be purchased for every person that wishes to use the publication within the same organization.
Customers who infringe these license terms are liable for a Global license fee.

听

Site License (PDF)*

This license allows for use of a publication by all users within one corporate location, e.g. a regional office.
These users may print out a single copy of the publication.
These users can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.
These users cannot share the publication (or any information contained therein) with any other person or persons outside the corporate location for which the publication is purchased.
Unless a Enterprise License is purchased, a Site User License must be purchased for every corporate location by an organization that wishes to use the publication within the same organization.
Customers who infringe these license terms are liable for a Global license fee.

听

Global License (PDF)*

This license allows for use of a publication by unlimited users within the purchasing organization e.g. all employees of a single company.
Each of these people may use the publication on any computer, and may print out the report, but may not share the publication (or any information contained therein) with any other person or persons outside of the organization.
These employees of purchasing organization can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.

*If Applicable.

91制片厂